Interleukin 2 and cancer Dotaz Zobrazit nápovědu
- MeSH
- interleukin-2 * MeSH
- lidé MeSH
- protinádorové látky * MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- interleukin-2 * MeSH
- protinádorové látky * MeSH
The aim of this review is to evaluate the results of IL-2 therapy of cancer two decades after the first experiments and to discuss whether and which results of local, systemic and adjuvant IL-2 therapy in preclinical models can be translated into clinics. The attention is also focused on the development and utilization of the IL-2 gene-modified tumour vaccines for therapeutic purposes. The prospects and limitations of both, IL-2 therapy and IL-2 gene therapy are discussed.
- MeSH
- genetická terapie * MeSH
- interleukin-2 genetika terapeutické užití MeSH
- lidé MeSH
- nádory farmakoterapie terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Názvy látek
- interleukin-2 MeSH
Local therapy with interleukin-2 (IL-2) and other cytokines may be a very effective way to treat cancer. This was the theme of the First Symposium on Local Cytokine Therapy of Cancer: Interleukin-2, Interferons and Related Cytokines, in Hamburg, 29 April-1 May 1999. The abstracts are published in Anticancer Research 19: 1995-2016 (1999). Here we present a report.
- MeSH
- interferony terapeutické užití MeSH
- interleukin-2 terapeutické užití MeSH
- lidé MeSH
- nádory terapie MeSH
- syntetické vakcíny terapeutické užití MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- interferony MeSH
- interleukin-2 MeSH
- syntetické vakcíny MeSH
- MeSH
- buňky K aktivované lymfokiny imunologie MeSH
- imunoterapie MeSH
- interleukin-2 terapeutické užití MeSH
- lidé MeSH
- nádory terapie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- interleukin-2 MeSH
- MeSH
- experimentální nádory farmakoterapie MeSH
- hodnocení léčiv MeSH
- imunologické faktory aplikace a dávkování škodlivé účinky terapeutické užití MeSH
- imunoterapie MeSH
- interleukin-2 aplikace a dávkování škodlivé účinky fyziologie terapeutické užití MeSH
- lidé MeSH
- nádory farmakoterapie patofyziologie MeSH
- receptory interleukinu-2 účinky léků fyziologie MeSH
- replikace DNA účinky léků MeSH
- T-lymfocyty účinky léků MeSH
- výsledek terapie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- úvodníky MeSH
- Názvy látek
- imunologické faktory MeSH
- interleukin-2 MeSH
- receptory interleukinu-2 MeSH
Peri-tumoural administration of human recombinant interleukin-2 (RIL-2) into C57BL/10ScSnPh (B10) mice carrying subcutaneous transplants of syngeneic methylcholanthrene (MC)-induced sarcomas substantially inhibited tumour growth. Experiments were designed to compare the tumour-inhibitory effect of highly purified RIL-2 with that of unpurified human and rat lymphoid interleukin-2 (IL-2) preparations. It was found that the effect of RIL-2 was significantly lower than that of the lymphoid IL-2 preparations. These findings indicate that other lymphokines may participate in the positive results of local IL-2 immunotherapy using unpurified lymphoid IL-2 preparations. However, the admixture of human recombinant interleukin-1 (RIL-1) did not potentiate the immunotherapeutic effects of RIL-2. Sensitivity of MC-induced sarcomas to local RIL-2 immunotherapy was a general phenomenon. The growth of approximately eighty percent (5/6) of the MC-induced sarcomas could be inhibited with local RIL-2 administration. Moreover, direct correlation between the sensitivity of tumours to the tumour-inhibitory effect of RIL-2 in vivo and their susceptibility to the cytolytic effect of RIL-2-activated syngeneic killer spleen (LAK) cells in vitro was observed. This correlation indicates that LAK cells represent the effector cell mechanism responsible for the anti-tumour efficacy of local RIL-2 immunotherapy and that in vitro testing of sensitivity to the LAK cell-mediated cytolysis may be used to detect tumours responding to the local RIL-2 immunotherapy in vivo.
- MeSH
- buňky NK imunologie MeSH
- cytotoxicita imunologická MeSH
- fibrosarkom imunologie terapie MeSH
- imunologická odpověď na dávku MeSH
- imunoterapie * MeSH
- interleukin-2 aplikace a dávkování izolace a purifikace terapeutické užití MeSH
- myši inbrední C57BL MeSH
- myši MeSH
- nádorové buňky kultivované imunologie MeSH
- transplantace izogenní MeSH
- transplantace nádorů MeSH
- zvířata MeSH
- Check Tag
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- interleukin-2 MeSH
It has been previously found that local administration of Balb/c plasmacytoma cells transformed and made non-tumorigenic by insertion of the cloned murine interleukin-2 (IL-2) gene induced regressions of a variety of murine tumours including the original Balb/c plasmacytoma X63-Ag8.653 growing in syngeneic mice. The tumour-inhibitory effect of the plasmacytoma cells transformed by IL-2 cDNA and designated as X63-m-IL-2 was due to their high constitutive production of IL-2. Here we show that admixture of syngeneic spleen cells to the X63-m-IL-2 transformants substantially (P < 0.025) increased the antitumour efficacy of the transformants. Balb/c spleen cells co-cultivated with X63-m-IL-2 cells in vitro yielded predominantly Thy 1.2+, CD3+, LFA-1+ lymphocytes, cytolytic for the X63-Ag8.653 plasmacytoma as well as for other murine tumours, including the X63-m-IL-2 target cells.
- MeSH
- buňky NK účinky léků fyziologie MeSH
- DNA genetika MeSH
- imunoterapie * MeSH
- interleukin-2 biosyntéza genetika MeSH
- myši inbrední BALB C MeSH
- myši MeSH
- nádorová transformace buněk genetika MeSH
- nádorové buňky kultivované MeSH
- nádory terapie MeSH
- plazmocytom genetika MeSH
- slezina cytologie imunologie MeSH
- transfekce * MeSH
- zvířata MeSH
- Check Tag
- mužské pohlaví MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- DNA MeSH
- interleukin-2 MeSH
- MeSH
- aktivace lymfocytů MeSH
- experimentální sarkom chemicky indukované imunologie MeSH
- interleukin-1 farmakologie MeSH
- interleukin-2 metabolismus farmakologie MeSH
- methylcholanthren MeSH
- myši inbrední C57BL MeSH
- myši MeSH
- receptory interleukinu-2 analýza metabolismus MeSH
- zvířata MeSH
- Check Tag
- mužské pohlaví MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- interleukin-1 MeSH
- interleukin-2 MeSH
- methylcholanthren MeSH
- receptory interleukinu-2 MeSH
Systemic IL-2 is an effective treatment for low to intermediate risk mRCC patients, its efficacy is marginal in high-risk cases. Therefore, other treatment approaches are required for this population. Ninety-four high-risk patients with RCC and pulmonary metastases were treated with inhaled plus concomitant low-dose subcutaneous rhIL-2. Clinical response, survival and safety were compared with those from IL-2 given systemically at the registered dose and schedule in 103 comparable historical controls. In the rhIL-2 INH group, treatment consisted of 6.5 MIU rhIL-2 nebulized 5x/day and 3.3 MIU rhIL-2 SC once daily. The rhIL-2 SYS group received treatment which consisted of intravenous infusion of 18.0 MIU/m2/day rhIL-2 or SC injection of 3.6-18.0 MIU rhIL-2. Some patients in both groups also received IFNalpha. Mean treatment durations were 43 weeks rhIL-2 INH and 15 weeks rhIL-2 SYS. Significantly longer overall survival and progression-free survival durations were observed in the rhIL-2 INH group. The probability of survival at 5 years was 21% for the rhIL-2 INH group. No patients survived 5 years in the rhIL-2 SYS group. A multivariate analysis of overall survival adjusting for differences in baseline characteristics between the two treatment groups resulted in a risk ratio of 0.43 (95% CI 0.30-0.63; P < 0.0001). The data suggested an association between the response (SD or better) and survival, especially in the rhIL-2 INH group. The inhalation regimen was well tolerated. This outcome study suggests that administration of rhIL-2 by inhalation is efficacious and safe in high-risk mRCC patients with pulmonary metastases, who have no other treatment option available.
- MeSH
- aplikace inhalační MeSH
- časové faktory MeSH
- dospělí MeSH
- injekce subkutánní MeSH
- interferon alfa aplikace a dávkování terapeutické užití MeSH
- interleukin-2 aplikace a dávkování škodlivé účinky terapeutické užití MeSH
- intravenózní infuze MeSH
- lidé středního věku MeSH
- lidé MeSH
- míra přežití MeSH
- nádory ledvin farmakoterapie MeSH
- nádory plic farmakoterapie sekundární MeSH
- rekombinantní proteiny aplikace a dávkování škodlivé účinky terapeutické užití MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- srovnávací studie MeSH
- Názvy látek
- interferon alfa MeSH
- interleukin-2 MeSH
- rekombinantní proteiny MeSH
The measurement of soluble interleukin-2 receptor in serum has been shown to be useful in a variety of clinical conditions. In autoimmune disorders sIL-2R level correlates with the disease activity and reflects in-vivo immune system activation. Markedly elevated sIL-2R levels were found in certain hematologic malignancies such as adult T-cell leukemia and hairy cell leukemia. In hairy cell leukemia it reflects the tumor burden and response to therapy and can be used as a reliable non-invasive marker of disease activity. The sIL-2R levels at diagnosis predict reliably prognosis in non-Hodgkin lymphoma and in Hodgkin's disease.
- MeSH
- autoimunitní nemoci diagnóza MeSH
- biologické markery krev MeSH
- hematologické nádory diagnóza MeSH
- lidé MeSH
- receptory interleukinu-2 krev MeSH
- rejekce štěpu diagnóza MeSH
- rozpustnost MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Názvy látek
- biologické markery MeSH
- receptory interleukinu-2 MeSH
